Optimal medical therapy improves outcomes in patients with diabetes mellitus and acute myocardial infarction.
Acute myocardial infarction
Diabetes
Optimal medical therapy
Percutaneous coronary intervention
Journal
Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
17
02
2023
revised:
10
07
2023
accepted:
17
07
2023
pubmed:
22
7
2023
medline:
22
7
2023
entrez:
21
7
2023
Statut:
ppublish
Résumé
We aimed to explored the association between the use of optimal medical therapy (OMT) in patients with myocardial infarction (AMI) and diabetes mellitus (DM) and clinical outcomes. Bleeding complications in a Multicenter registry of patients discharged with diagnosis of Acute Coronary Syndrome (BleeMACS) is an international registry that enrolled participants with acute coronary syndrome followed up for at least 1 year across 15 centers from 2003 to 2014. Baseline characteristics and endpoints were analyzed. Among 3095 (23.2%) patients with AMI and DM, 1898 (61.3%) received OMT at hospital discharge. OMT was associated with significantly reduced mortality (4.3% vs. 10.8%, p < 0.001), re-AMI (4.4% vs. 8.1%, p < 0.001), and composite endpoint of death/re-AMI (8.0% vs. 17.6%, p < 0.001). No difference was observed among regions. Propensity score matching confirmed that OMT significantly associated with lower mortality. After adjusting for confounding variables, OMT, drug-eluting stents, and complete revascularization were independent protective factors of 1-year mortality, whereas left ventricular ejection fraction and age were risk factors. Guideline-recommended OMT was prescribed at suboptimal frequencies with geographic variations in this worldwide cohort. OMT can improve long-term clinical outcomes in patients with DM and AMI. NCT02466854 June 9, 2015.
Identifiants
pubmed: 37478977
pii: S0168-8227(23)00596-X
doi: 10.1016/j.diabres.2023.110833
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT02466854']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110833Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.